AAPharmaSyn
AAPharmaSyn, LLC is an American contract research organization (CRO) based in Ann Arbor, Michigan. Founded in 2006, AAPharmaSyn provides synthetic and medicinal chemistry services to the pharmaceutical industry.[1][2]
History
AAPharmaSyn was formed in Ann Arbor after Pfizer layoffs in 2005. After losing their jobs and not wanting to move, former Pfizer chemists Xue-Min Cheng and Helen T. Lee formed the company and were later joined by Gary L. Bolton.[3] By late 2008, AAPharmaSyn employed 10 people and had worked with approximately 22 clients.[3]
In 2020 the ownership of AAPharmaSyn was transitioned to a strategic investor.[2]
Government support and awards
In 2006, the company secured a $750,000 loan from the Michigan Economic Development Corporation to support its growing operations.[4][3]
The company was also successful in securing government contracts from the Department of Defense and NIH. AAPharmaSyn was the recipient of a U.S. Department of Defense contract for experimental therapeutics medicinal chemistry[5] and was also awarded an NIAID indefinite-delivery contract for interventional agents chemistry services.[6][7]
Collaborations
In 2025, AAPharmaSyn was announced as one of the three companies in the A2 BioPharm Collaborative, alongside AnchorBio and TSRL. AAPharmaSyn contributed synthetic chemistry, process development, and lead-optimization capabilities to the integrated drug development collaborative.[8]
Patent activity
AAPharmaSyn LLC as a current assignee or co-assignee on several United States patent records, including Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses (US11292781B2 and US12195443B2),[9][10] C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses (US11584775B2),[11] Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators (US11814338B2),[12] Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway (US11827664B2),[13] and Synthetic triterpenoids with nitrogen-based substituents at C-17 and methods of use thereof (US20230111914A1).[14][lower-alpha 1]
Mentions in scientific literature
AAPharmaSyn provides custom compounds to multiple researchers and has been acknowledged in scientific publications as a synthesis or supply source for research compounds such as STX,[15] ATR-101,[16] and a valyl gemcitabine prodrug.[17]
Notes
- ↑ Google Patents states that its listed current assignees may be inaccurate and that it has not performed a legal analysis of patent ownership.
References
- ↑ "About AAPharmasyn". CPHI Online. Informa Markets. Retrieved July 24, 2026.
- ↑ 2.0 2.1 AAPharmaSyn (Spring 2024). "A Reputation for Solving Tough Chemistry Problems". BioMatters. MichBio. pp. 24–25.
- ↑ 3.0 3.1 3.2 McCoy, Michael (December 8, 2008). "Life After Big Pharma". Chemical & Engineering News. Vol. 86 no. 49. Retrieved July 24, 2026.
- ↑ 21st Century Jobs Fund Program: Year-End Report to the Legislature for Fiscal Year 2008 (PDF) (Report). Michigan Economic Development Corporation. 2008. Retrieved July 24, 2026.
- ↑ "Contract Award W81XWH19F0041 to AAPharmaSyn LLC". USAspending.gov. United States Department of the Treasury. Retrieved July 24, 2026.
- ↑ "75N93025D00006 – Interventional Agents Chemistry Services". HigherGov. Retrieved July 24, 2026.
- ↑ "Interventional Agents Chemistry Services". SAM.gov. United States General Services Administration. Notice ID 75N93024R00002. Retrieved July 24, 2026.
- ↑ "Ann Arbor-based Life Science Companies TSRL, AnchorBio, and AAPharmaSyn Launch the A2 BioPharm Collaborative at BIO 2025". TSRL. June 18, 2025. Retrieved July 24, 2026.
- ↑ "US11292781B2 – Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses". Google Patents. Retrieved July 24, 2026.
- ↑ "US12195443B2 – Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses". Google Patents. Retrieved July 24, 2026.
- ↑ "US11584775B2 – C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses". Google Patents. Retrieved July 24, 2026.
- ↑ "US11814338B2 – Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators". Google Patents. Retrieved July 24, 2026.
- ↑ "US11827664B2 – Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway". Google Patents. Retrieved July 24, 2026.
- ↑ "US20230111914A1 – Synthetic triterpenoids with nitrogen-based substituents at C-17 and methods of use thereof". Google Patents. Retrieved July 24, 2026.
- ↑ Gray, Nora E.; Zweig, Jonathan A.; Kawamoto, Colleen; Quinn, Joseph F.; Copenhaver, Philip F. (2016). "STX, a Novel Membrane Estrogen Receptor Ligand, Protects Against Amyloid-β Toxicity". Journal of Alzheimer's Disease. 51 (2): 391–403. doi:10.3233/JAD-150756. PMC 4961356. PMID 26890746.CS1 maint: PMC format (link)
- ↑ Cheng, Yunhui; Kerppola, Raili Emilia; Kerppola, Tom Klaus (2016). "ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo". Endocrine-Related Cancer. 23 (4): 1–19. doi:10.1530/ERC-15-0527. PMC 4887102. PMID 26843528.CS1 maint: PMC format (link)
- ↑ Thompson, Brian R.; Shi, Jian; Zhu, Hao-Jie; Smith, David E. (2020). "Pharmacokinetics of Gemcitabine and its Amino Acid Ester Prodrug following Intravenous and Oral Administrations in Mice". Biochemical Pharmacology. 180: 114127. doi:10.1016/j.bcp.2020.114127. PMC PMC7606647 Check
|pmc=value (help). PMID 32603666 Check|pmid=value (help).CS1 maint: PMC format (link)
External links
References
This article "AAPharmaSyn" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:AAPharmaSyn. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
